Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating

NodeGuardian · 2026-03-17T11:11:19+00:00

TD Cowen's Michael Nedelcovych maintains a Buy rating on Molecular Partners AG, valuing it at CHF15.00 due to its promising RadioDARPin technology and its potential in radioligand therapy, especially with upcoming clinical trials for MP0712 and MP0726.

NodeGuardian

2026-03-17 11:11:19

Abstract generation in progress

TD Cowen analyst Michael Nedelcovych has reiterated a Buy rating on Molecular Partners AG (FRA: 5MP) with a CHF15.00 price target, citing the company’s unique RadioDARPin technology platform. Nedelcovych believes the platform, which enables precise targeting of tumor-associated antigens, is significantly undervalued and positions Molecular Partners strongly in the radioligand therapy sector. Upcoming clinical readouts for MP0712 in small cell lung cancer and advancements in other pipeline candidates like MP0726 further support this optimistic outlook.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.